Adarezza Ferrer, MD
Psychiatry · San Diego, CANPI 1316175524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,017 and has fallen 98.2% since, to $19 in 2025.
Across 113 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$732
- Teva Pharmaceuticals USA, Inc.$691
- Otsuka America Pharmaceutical, Inc.$486
- Sunovion Pharmaceuticals Inc.$361
- Indivior Inc.$353
- Johnson & Johnson$229
- plus $364 from 6 others
What the payments were for
- Food & beverage$3,215100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $732 |
| Teva Pharmaceuticals USA, Inc. | 18 | $691 |
| Otsuka America Pharmaceutical, Inc. | 16 | $486 |
| Sunovion Pharmaceuticals Inc. | 20 | $361 |
| Indivior Inc. | 14 | $353 |
| Johnson & Johnson | 11 | $229 |
| Alkermes, Inc. | 2 | $224 |
| Lundbeck LLC | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 3 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$897
- VRAYLAR$480
- AUSTEDO$126
- Austedo XR$122
- REXULTI$122
- LATUDA$121
- ABILIFY MAINTENA$120
How this compares
$3,215 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 72 | $210,399 |
| IngrezzaValbenazine Tosylate | 11 | $84,100 |
| Abilify MaintenaAripiprazole | 15 | $37,664 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $22,910 |
| Lurasidone Hcl | 51 | $4,899 |
| Paliperidone ErPaliperidone | 55 | $3,870 |
| Clozapine | 32 | $2,205 |
| Divalproex Sodium ErDivalproex Sodium | 34 | $1,935 |
| Quetiapine Fumarate | 240 | $1,905 |
| Trazodone Hcl | 164 | $1,316 |
| Aripiprazole | 74 | $914 |
| Divalproex Sodium | 94 | $791 |
| Haloperidol Decanoate | 19 | $693 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 65 | $540 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 23 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $229 | $210,39972 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $16 | $84,10011 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $486 | $37,66415 claims |
| Alkermes, Inc.Lybalvi | $224 | $22,91015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Jonathan MeyerSan Diego$2.3M
- Sanjai RaoSan Diego$445K
- Murray SteinSan Diego$121K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.